Pivmecillinam

(Pivya®)

Pivya®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 185 mg)
Drug ClassPenicillin class antibacterials
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one randomized controlled trial. [1]
  • Of the 143 non-pregnant women aged 18-60 included in the final analysis, 53.8% (77 women) recovered without antibiotics, while 46.2% (66 women) were prescribed antibiotics following initial ibuprofen treatment for uncomplicated UTIs. No significant baseline predictors were identified for the need for antibiotic treatment in the adjusted model. The area under the curve (AUC) for the model was 0.66 (95% confidence interval (CI): 0.57 to 0.74), indicating moderate predictive accuracy for antibiotic use.
  • There is no safety information available in the reviewed studies.
  • There is no population type or subgroup information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Pivya (pivmecillinam) Prescribing Information.2024Utility therapeutics Ltd., UK

Randomized Controlled Trials